PR Newswire BiotechOriginal article
Cell Stem Cell: Die tBE-vermittelte Base-Editing-Therapie erzielt bei unterschiedlichen genetischen Hintergründen eine dauerhafte klinische Remission bei Sichelzellkrankheit und β-Thalassämie
Data ReadoutpositivetBEPositive
AI Analysis
Summary
A study published in Cell Stem Cell demonstrates that tBE-mediated base editing therapy achieves sustained clinical remission in sickle cell disease and transfusion-independent status in beta-thalassemia across diverse patient populations including African SCD patients and South/Southeast Asian patients.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
tBE-mediated base editing therapy achieved sustained clinical remission in sickle cell disease patients and transfusion-independent status in beta-thalassemia patients across different genetic backgrounds (African SCD patients and South/Southeast Asian TDT patients)
Importance:7/10
Sentiment:
0.85
base editinggene therapysickle cell diseasebeta-thalassemiaclinical remissiontransfusion independence
Read the original article
Published by PR Newswire Biotech on September 8, 2026 4:52 PM